INTRODUCTION {#s1}
============

Incontrovertibly and unfortunately, lung cancer is the most frequent reason of cancer-related deaths all over the world \[[@R1]\]. It is roughly estimated that there are 1.83 million new lung cancer cases and 1.59 million deaths annually around the world \[[@R2]\]. Approximately 83% of lung cancer patients are non-small cell lung cancer (NSCLC) patients, which 21% of those are alive at five years \[[@R3]\]. More powerful methods of diagnosis and treatment are indispensable to need for lung cancer patients.

Cancer stem cells (CSCs) could divide to produce heterogeneous lineages of cancer cells and new stem cells \[[@R4]\], which are making up a minority portion of the solid tumors, resisting to chemotherapy and radiation, correlating with targeted drug resistance and organ metastasis \[[@R5], [@R6]\]. This notion that tumors are maintained by their own stem cells has brought about novel directions to reveal the mechanisms of occurrence, progression, drug resistance, and metastasis of tumors and further seek for effective treatments of tumors. CD133 antigen, also known as prominin-1, is a member of pentaspan transmembrane glycoproteins specifically locating to cellular protrusions \[[@R7], [@R8]\]. It has been used extensively as a biomarker of CSCs in different types of cancers, such as hepatic cancer, gallbladder cancer, breast cancer, gastric cancer, pancreatic cancer and lung cancer \[[@R9]--[@R14]\].

Racial difference strongly affects the molecular characteristics of lung cancer \[[@R15]\]. Epidermal growth factor receptor mutations (mEGFR) and kirsten rat sarcoma viral oncogene mutations (mKRAS) are the most common mutations in lung cancer \[[@R16]\]. Alternatively, mEGFR and mKRAS usually do not occur in the same individual and have a significant association with race. For instance, Asian population have more frequently mEGFR but Caucasian population have more frequently mKRAS \[[@R17], [@R18]\]. Furthermore, it has been demonstrated that CD133 overexpressed in gefitinib-resistant tumors (GRTs) of EGFR-mutant NSCLC \[[@R19]\]. Therefore, we speculate that the prognostic value of CD133 in NSCLC patients might depend on given race because of various molecular characteristics.

Previous several studies about the prognostic value of CD133 in NSCLC patients suggested that NSCLC patients with higher CD133 expression have shorter overall survival (OS) time \[[@R9], [@R20]--[@R26]\] and disease free survival (DFS) \[[@R27], [@R28]\] time. On the contrary, several studies indicated that the expression level of CD133 was no association with OS and DFS \[[@R20], [@R29]--[@R35]\]. Additional, the relationship between CD133 and clinicopathological features was also in dispute \[[@R9], [@R20]--[@R22], [@R24]--[@R27], [@R29], [@R31], [@R33], [@R35]--[@R48]\], such as age, gender, smoking history, T stage, lymph node metastasis, distant metastasis, TNM stage, differentiation grade, and histological type. Wu. H et al. \[[@R49]\] and Wang. W et al. \[[@R50]\] have performed a meta-analysis on the prognostic value of CD133 expression in NSCLC patients, respectively. However, only 23 studies and 13 studies were included in their meta-analysis published in 2014, respectively. Additionally, several reduplicative articles (Okudela. K \[[@R28]\] and Woo. T \[[@R51]\]; Wei. YP \[[@R24]\] and Zhang. HZ \[[@R52]\]) in their meta-analysis which may limit the reliability of conclusion. Furthermore, their studies did not clarify the source of significant heterogeneity with sufficient subgroup analysis and sensitive analysis.

We performed this meta-analysis comprehensively to obtain further evidence that the biomarker of CSCs CD133 expression level may be associated with the prognosis of NSCLC patients and try to demonstrate our speculation that the prognostic value of CD133 in NSCLC patients might depend on given race for various molecular characteristics. Further, it may provide supportive evidence for the association between the cancer stem cells and the drive gene mutations of lung cancer in clinical trials and broaden new therapeutic strategy of NSCLC.

RESULTS {#s2}
=======

Eligible studies {#s2_1}
----------------

We used the PRISMA 2009 flow diagram to screen the literature in Figure [1](#F1){ref-type="fig"} \[[@R53]\]. A total of 1091 literature was identified through original searching from PubMed, Embase, and Web of Science. In total, 1009 Irrelevant and duplicate records were excluded through title review by two author independently (Engeng Chen and Zhiru Zeng). After that, we sorted the left literature through abstract review with double check and excluded 47 literature of meeting reports and reviews. Then we assessed the full text in the left thirty-five articles, and abandoned three articles that the sample data were reduplicate or insufficient. At last, 32 studies with 3595 participants were eligible in this meta-analysis.

![Flow diagram of study selection](oncotarget-07-56526-g001){#F1}

Study characteristics and quality assessment {#s2_2}
--------------------------------------------

The main characteristics of eligible studies were summarized in Table [1](#T1){ref-type="table"}. The publication year was from 2008 to 2015. The race of study population was determined by its country. 18 Chinese studies and 4 Japanese studies composed East Asian ethnicity, and the Caucasian were from 3 Italian studies, 3 German studies, 1 Swiss study, 1 Czech study, 1 Australian study, 1 American study. Approximately 2412 male and 1183 female composed 3595 NSCLC patients in this meta-analysis, with the mean/median age range from 59 to 74.2. We defined overall survival (OS) and disease free survival (DFS) as primary endpoints. 15 studies \[[@R9], [@R20]--[@R26], [@R30]--[@R32], [@R42], [@R44], [@R54], [@R55]\] and 10 studies \[[@R20], [@R27]--[@R35]\] contained OS and DFS, respectively. Most of studies (29/32) used immunological histological chemistry (IHC) as experimental method for detecting CD133, and the left studies (3/32) chose quantitative real-time polymerase chain reaction (Q-PCR).

###### Characteristics of eligible studies in the meta-analysis

  Study                  Year   Race        Patient(M/F)    Age             TNM      CD133 positive threshold   CD133 positive ratio   Method       Primary endpoint   NOS score
  ---------------------- ------ ----------- --------------- --------------- -------- -------------------------- ---------------------- ------------ ------------------ -----------
  **Alamgeer.M**         2013   Caucasian   205 (125/80)    70 (median)     I        ≥ 5%                       68.7%                  IHC          OS + DFS           8
  **Bertolini.G**        2009   Caucasian   42 (29/13)      NA              I--IV    ≥ 5%                       23.8%                  IHC/FACS     DFS                7
  **Cheng.J.R**          2010   Asian       65 (58/7)       62.5 (mean)     I--III   \> 10%                     69.2%                  IHC          NA                 5
  **Cortes-Dericks.L**   2012   Caucasian   64 (34/30)      62 (median)     I--III   NA                         NA                     qRT-PCR      DFS                8
  **Gao.Y**              2015   Asian       62 (40/22)      64 (mean)       NA       ≥ 5%                       51.6%                  IHC          NA                 5
  **Gottschling.S**      2013   Caucasian   100 (75/25)     63.4 (mean)     I--II    ≥ 10%                      18%                    IHC          OS + DFS           8
  **Gu.Y.P**             2010   Asian       44 (27/17)      62.5 (mean)     I--III   \> 10%                     68.2%                  IHC          NA                 5
  **Herpel.E**           2011   Caucasian   86 (61/25)      64 (mean)       I--II    \> 0                       15.1%                  IHC          OS + DFS           8
  **Huang.M.J**          2015   Asian       239 (180/59)    63 (median)     I--IV    \> 10%                     52.3%                  IHC          OS                 5
  **Janikova.M**         2010   Asian       121 (95/26)     NA              NA       \> 10%                     19%                    TMA/IHC      OS + DFS           7
  **Le.H.B**             2013   Asian       30 (23/7)       61.5 (median)   I--IV    NA                         NA                     qRT-PCR      OS                 7
  **Li.F**               2011   Asian       145 (111/34)    59.6 (mean)     I        \> 1%                      31.7%                  IHC          DFS                8
  **Li.H**               2011   Asian       90 (71/19)      59.5(median)    I--IV    ≥ 10%                      48.9%                  IHC          NA                 5
  **Li.L.D**             2013   Asian       112 (94/18)     59.2 (median)   I--IV    NA                         NA                     qRT-PCR      NA                 5
  **Lin.X.Y**            2009   Asian       54              NA              NA       \> 0                       50%                    IHC          NA                 4
  **Mizugaki.H**         2013   Asian       161 (109/52)    NA              I--IV    NA                         77%                    IHC          OS                 7
  **Okudela.K**          2012   Asian       177 (89/88)     68 (median)     I        ≥ 17.5%                    45.8%                  IHC          DFS                8
  **Pirozzi.G**          2013   Caucasian   45 (31/14)      74.2 (median)   I--III   ≥ 10%                      26.7%                  FC/IHC/PCR   DFS                8
  **Qiu.Z.X**            2015   Asian       175 (130/45)    NA              I--IV    \> 3.5 score               56.6%                  IHC          OS                 7
  **Salnikov.A.V**       2010   Caucasian   88 (79/9)       59.1 (mean)     I--III   ≥ 20%                      63%                    IHC          OS                 8
  **Shien.K**            2012   Asian       30 (21/9)       NA              III      \> 1%                      30%                    IHC          DFS                7
  **Song.S.M**           2014   Asian       90 (52/38)      NA              I--III   \> 4 score                 61.11%                 IHC          NA                 5
  **Sowa**               2015   Asian       239 (123/116)   67 (mean)       I--III   \> 2 score                 10.9%                  TMA/IHC      OS                 8
  **Su.C.X**             2015   Asian       159 (87/72)     61 (median)     I--III   \> 100 score               44%                    IHC          OS                 8
  **Sullivan.J.P**       2010   Caucasian   207             NA              I        NA                         27%                    TMA/IHC      OS                 7
  **Sun.H.Y**            2012   Asian       67 (53/14)      60.3 (mean)     I--III   \> 3 score                 62\. 69%               IHC          NA                 5
  **Tirino.V**           2009   Caucasian   89 (59/30)      NA              I--IV    NA                         71.9%                  IHC          NA                 5
  **Wang.S.G**           2012   Asian       83 (45/38)      NA              NA       NA                         81.9%                  IHC          NA                 4
  **Wei.Y.P**            2008   Asian       77 (57/20)      63 (median)     NA       \> 10%                     51.9%                  IHC          OS                 7
  **Wu.S.W**             2012   Asian       305 (233/72)    59.8 (media)    I--III   \> 10%                     48.9%                  IHC          OS                 8
  **Xu.Y.H**             2010   Asian       102 (66/36)     60.51 (mean)    I--IV    ≥ 10%                      50%                    IHC          OS                 8
  **Yao.J**              2010   Asian       42 (24/18)      59 (median)     NA       \> 10%                     73.8%                  IHC          NA                 5

The quality of studies were assessed by Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@R56]\]. 62.5% (20/32) of studies were more than 6 score which were deemed as high quality studies (see [Supplementary Table S1](#SD1){ref-type="supplementary-material"} in Supplementary Material).

Association between CD133 and OS {#s2_3}
--------------------------------

Random-effects model was used to analyze the HRs of OS from 15 eligible studies because of significant heterogeneity (I^2^ = 83.7%, *p* \< 0.001). NSCLC patients with higher CD133 expression showed a shorter OS time (HR = 1.98, 95% CI: 1.30--3.02, *p* = 0.002; I^2^ = 83.7%) (Figure [2A](#F2){ref-type="fig"}). Subgroup analysis indicated that both race and sample size were contributed to substantial heterogeneity. The subgroup of Caucasian from 6 studies was contributed to tiny heterogeneity (I^2^ = 0%, *p* = 0.426; HR = 1.15, 95% CI: 0.88--1.52, *p* = 0.307), while the subgroup of Asian from 9 studies was contributed to subtotal heterogeneity (I^2^ = 82.7%, *p* \< 0.001; HR = 2.59, 95% CI: 1.58--4.25, *p* \< 0.001). (Figure [3A](#F3){ref-type="fig"}). In consideration of significant heterogeneity in the subgroup of Asian, we continued to divide the 9 Asian studies into groups by sample size. The pooled HR of studies with large sample size (*n* \> 100) was 2.83 (95% CI: 1.63--4.90, *p* \< 0.001; I^2^ = 85.5%, *p* \< 0.001) (Figure [3C](#F3){ref-type="fig"}). Sensitive analysis in Asian studies with large sample size showed that whatever study was removed, the result was stable as before (see [Supplementary Figure S1](#SD1){ref-type="supplementary-material"} in Supplementary Material). Furthermore, the heterogeneity decreased (I^2^ = 32%, *p* = 0.196) after dropped out one study (Su. C.X 2015) (HR = 3.80, 95% CI: 3.12--4.04, *p* \< 0.001) (Figure [3D](#F3){ref-type="fig"}). These results suggested that NSCLC patients with higher CD133 expression had poor prognosis only in Asian patients but not in Caucasian patients, which was quite different from the conclusion of Wang. W et al. \[[@R50]\]. Additionally, the subgroup analysis on OS by sample size showed studies with large sample size (*n* \> 100) were associated with OS (HR = 2.45, 95% CI: 1.45--4.03, *p* = 0.001; I^2^ = 87.4%, *p* \< 0.001) but not studies with small sample size (≤ 100) (HR = 1.28, 95% CI: 0.71--2.29, *p* = 0.415; I^2^ = 40.8%, *p* = 0.149) (Figure [3B](#F3){ref-type="fig"}), and neither Wu. H et al. \[[@R24]\] nor Wang. W et al. \[[@R25]\] analyzed this in their studies.
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Association between CD133 and DFS {#s2_4}
---------------------------------

Fixed-effects model was used to analyze the HRs of DFS from 10 eligible studies for tiny heterogeneity (I^2^ = 34%, *p* = 0.136). No significant association was found between CD133 expression level and DFS in NSCLC patients (HR = 1.22, 95% CI: 0.92--1.62, *p* = 0.173) (Figure [2B](#F2){ref-type="fig"}). Though the heterogeneity was no significant (I^2^ = 34%, *p* = 0.136), the subgroup analysis by race and sample size were still performed. The results showed that there was no significant association between CD133 expression level and DFS in NSCLC patients by dividing race and sample into groups (see [Supplementary Figure S2](#SD1){ref-type="supplementary-material"} in Supplementary Material).

Association between CD133 and clinicopathological features {#s2_5}
----------------------------------------------------------

The frequency distributions of clinicopathological features in NSCLC patients with negative and positive expression of CD133 were summarized in Table [2](#T2){ref-type="table"}. The pooled ORs of CD133 expression level and clinicopathological features were summarized in Figure [4](#F4){ref-type="fig"}. There were no associations between CD133 expression level and age, gender, smoking history, T stage, distant metastasis or TNM stage (detailed forest plot figures see [Supplementary Figure S3--S8](#SD1){ref-type="supplementary-material"} in Supplementary Material). However, higher CD133 expression level was associated with poor/moderate differentiation (OR = 2.03, 95% CI: 1.32--3.14, *p* = 0.001; I^2^ = 54.8%, *p* = 0.007), lymph node metastasis (OR = 2.39, 95% CI: 1.62--3.52, *p* \< 0.001; I^2^ = 61.5%, *p* = 0.001) and histological type (OR = 1.21, 95% CI: 1.01--1.46, *p* = 0.041; I^2^ = 21.8%, *p* = 0.18) (detailed forest plot figures see [Supplementary Figure S9](#SD1){ref-type="supplementary-material"}--[S11](#SD1){ref-type="supplementary-material"} in Supplementary Material).

###### The frequency distribution of clinicopathological features in NSCLC patients with negative and positive expression of CD133

  Study                  Age(old/young)   Gender(M/F)   Smoke(Y/N)   T stage(T3/4 vs.T1/2)   Lymph node Met (Y/N)                                                                                                                
  ---------------------- ---------------- ------------- ------------ ----------------------- ---------------------- ----- ---- ----- ----- ------- ---- ----- ---- ---- ------- ---- ---- ---- ---- ------- ---- ---- ----- ---- --------
  **CD133**              −                \+            *p*          −                       \+                     *p*   −    \+    *p*   −       \+   *p*   −    \+   *p*                                                      
  **Alamgeer.M**         52               46            52           55                      0.58                   39    41   65    60    0.67    12   11    92   90   1       \-   \-   \-   \-   \-      88   80   16    15   1
  **Bertolini.G**        16               3             16           7                       0.31                   4     9    6     23    0.7     1    8     9    24   0.42    \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Cheng.J.R**          \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      12   13   33    7    0.005
  **Cortes-Dericks.L**   \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Gao.Y**              9                14            21           28                      0.3                    10    12   22    18    0.6     \-   \-    \-   \-   \-      8    7    24   23   1       11   18   21    12   0.043
  **Gottschling.S**      \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Gu.Y.P**             14               4             16           10                      0.419                  9     8    21    6     0.085   16   10    14   4    0.419   28   13   2    1    1       9    3    21    11   0.817
  **Herpel.E**           \-               \-            \-           \-                      \-                     3     22   10    51    0.853   \-   \-    \-   \-   \-      13   72   1    2    0.971   10   51   3     22   0.853
  **Huang.M.J**          47               41            78           73                      0.793                  32    27   93    87    0.732   \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Janikova.M**         \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Le.H.B**             \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Li.F**               \-               \-            \-           \-                      \-                     9     25   37    74    0.452   18   31    28   68   0.354   \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Li.H**               19               25            25           21                      0.289                  7     12   37    34    0.237   \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      4    15   40    31   0.013
  **Li.L.D**             48               9             48           7                       0.643                  16    4    80    14    0.817   \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Lin.X.Y**            \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-                                  7    17   20    10   0.006
  **Mizugaki.H**         60               20            64           17                      0.545                  43    9    81    28    0.237   38   12    72   24   0.894   33   10   91   27   0.96    77   29   47    8    0.067
  **Okudela.K**          \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Pirozzi.G**          \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Qiu.Z.X**            46               45            53           31                      0.094                  23    22   76    54    0.391   \-   \-    \-   \-   \-      63   51   36   25   0.633   53   43   46    33   0.688
  **Salnikov.A.V**       \-               \-            \-           \-                      \-                     6     3    50    29    1       \-   \-    \-   \-   \-      16   12   40   20   0.387   \-   \-   \-    \-   \-
  **Shien.K**            12               9             3            6                       0.426                  2     7    7     14    0.862   1    7     8    14   0.417   \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Song.S.M**           \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      16   21   39    14   0.004
  **Sowa**               \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Su.C.X**             36               43            41           39                      0.474                  37    35   40    47    0.497   44   47    33   35   0.982   \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Sullivan.J.P**       \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Sun.H.Y**            20               9             22           16                      0.353                  7     7    36    17    0.213   14   12    28   13   0.233   \-   \-   \-   \-   \-      \-   \-   \-    \-   \-
  **Tirino.V**           22               11            42           14                      0.398                  25    5    39    20    0.087                                51   20   13   5    0.974   55   20   9     5    0.489
  **Wang.S.G**           21               8             13           3                       0.766                  \-    \-   \-    \-    \-      34   4     34   11   0.175   \-   \-   \-   \-   \-      11   10   57    5    0.0001
  **Wei.Y.P**            \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      15   23   25    15   0.042
  **Wu.S.W**             64               76            85           79                      0.2888                 33    39   116   117   0.558   \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      35   85   114   71   0.0001
  **Xu.Y.H**             35               35            16           16                      1                      181   18   33    33    1       29   25    22   26   0.427   16   15   35   36   0.83    14   20   37    31   0.208
  **Yao.J**              \-               \-            \-           \-                      \-                     \-    \-   \-    \-    \-      \-   \-    \-   \-   \-      \-   \-   \-   \-   \-      7    8    24    3    0.009

  Study                  Metastasis(Y/N)   TNM stage(III/IV vs. I/II)   Differentiation (moderate and poor vs. well)   histology(ADC/SSC)                                                                                                
  ---------------------- ----------------- ---------------------------- ---------------------------------------------- -------------------- ------- ----- ----- ----- ----- ------- ---- ----- ----- ----- -------- ---- ----- ---- ---- -------
  **CD133**              −                 \+                           *p*                                            −                    \+      *p*   −     \+    *p*   −       \+   *p*                                             
  **Alamgeer.M**         \-                \-                           \-                                             \-                   \-      81    63    23    28    0.022   \-   \-    \-    \-    \-       31   53    73   48   0.001
  **Bertolini.G**        \-                \-                           \-                                             \-                   \-      23    20    9     6     0.767   \-   \-    \-    \-    \-       1    13    8    17   0.119
  **Cheng.J.R**          \-                \-                           \-                                             \-                   \-      30    13    15    7     1       17   6     28    14    0.588    21   13    10   4    0.741
  **Cortes-Dericks.L**   \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Gao.Y**              16                20                           16                                             10                   0.184   \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       15   12    11   14   0.579
  **Gottschling.S**      \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Gu.Y.P**             24                13                           6                                              1                    0.52    \-    \-    \-    \-    \-      25   13    5     1     0.7      15   4     8    4    0.734
  **Herpel.E**           \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       4    30    8    28   0.399
  **Huang.M.J**          \-                \-                           \-                                             \-                   \-      91    91    34    23    0.203   2    14    123   100   0.002    63   62    23   23   1.935
  **Janikova.M**         \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Le.H.B**             \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Li.F**               \-                \-                           \-                                             \-                   \-      14    31    32    68    0.915   \-   \-    \-    \-    \-       28   57    18   42   0.708
  **Li.H**               \-                \-                           \-                                             \-                   \-      18    26    26    20    0.139   \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Li.L.D**             \-                \-                           \-                                             \-                   \-      11    2     74    13    1       21   7     48    7     0.158    43   13    16   1    0.216
  **Lin.X.Y**            \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      6    15    21    12    0.012    \-   \-    \-   \-   \-
  **Mizugaki.H**         \-                \-                           \-                                             \-                   \-      67    27    57    10    0.04    33   12    85    18    0.201    51   15    66   19   0.956
  **Okudela.K**          \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Pirozzi.G**          \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Qiu.Z.X**            103               72                           4                                              4                    0.896   40    64    35    36    0.109   39   33    59    43    0.63     45   29    46   45   0.187
  **Salnikov.A.V**       22                8                            34                                             24                   0.174   13    11    43    21    0.258   \-   \-    \-    \-    \-       27   16    19   13   0.764
  **Shien.K**            \-                \-                           \-                                             \-                   \-      9     12    1     8     0.205   \-   \-    \-    \-    \-       3    7     6    14   1
  **Song.S.M**           \-                \-                           \-                                             \-                   \-      49    32    6     3     1       8    10    47    25    0.105    25   16    30   19   0.981
  **Sowa**               \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Su.C.X**             \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       26   39    51   43   0.077
  **Sullivan.J.P**       \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       \-   \-    \-   \-   \-
  **Sun.H.Y**            17                18                           25                                             7                    0.012   27    19    15    6     0.317   7    9     35    16    0.073    16   11    26   14   0.643
  **Tirino.V**           \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      \-   \-    \-    \-    \-       23   9     35   14   0.965
  **Wang.S.G**           \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      61   11    7     4     0.203    \-   \-    \-   \-   \-
  **Wei.Y.P**            \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      16   19    24    18    0.318    14   11    20   20   0.638
  **Wu.S.W**             \-                \-                           \-                                             \-                   \-      29    111   120   45    0.001   4    30    145   126   0.0001   99   111   50   45   0.375
  **Xu.Y.H**             48                47                           3                                              4                    1       \-    \-    \-    \-    \-      30   42    21    9     0.009    24   27    25   21   0.473
  **Yao.J**              \-                \-                           \-                                             \-                   \-      \-    \-    \-    \-    \-      12   4     19    7     1        8    7     16   2    0.047

![Clustered bars of pooled ORs for the association of CD133 expression with clinicopathological features in NSCLC patients](oncotarget-07-56526-g004){#F4}

We performed subgroup analysis regularly. Concerning differentiation, subgroup analysis by sample size but not race was performed due to all eligible studies were Asian. Large sample size group (*n* \> 100) was contributed to the main heterogeneity (I^2^ = 66.0%, *p* = 0.012) with significant association (OR = 2.86, 95% CI: 1.46--5.58, *p* = 0.002) but not small sample size group (OR = 1.51, 95% CI: 0.85--2.68, *p* = 0.162; I^2^ = 42.9%, *p* = 0.092) (Figure [5A](#F5){ref-type="fig"}). As for lymph node metastasis, subgroup analysis by sample size could not explain the source of heterogeneity but race could (see [Supplementary Figure S12](#SD1){ref-type="supplementary-material"} in Supplementary Material). The subgroup analysis by race showed that Asian group was contributed to a large proportion of heterogeneity (I^2^ = 52.7%, *p* = 0.013) with significant association (OR = 2.97, 95% CI: 2.03--4.34, *p* \< 0.001) compared with Caucasian group (OR = 0.87, 95% CI: 0.48--1.56, *p* = 0.638; I^2^ = 0%, *p* = 0.768) (Figure [5B](#F5){ref-type="fig"}). These results suggested that NSCLC patients with higher CD133 expression had poor prognosis only in Asian patients but not in Caucasian patients.

![The subgroup analysis exploring the significant heterogeneity of CD133 expression with (A) differentiation by sample size (B) lymph node metastasis by race (C) histological type (adenocarcinoma vs. Squamous-cell carcinoma) after removed one study](oncotarget-07-56526-g005){#F5}

It seemed that the expression of CD133 in lung adenocarcinoma patients (ADC) was more than in lung squamous-cell carcinoma (SCC) patients, which was in agreement with Wang. W et al. \[[@R25]\]. However, sensitive analysis showed that the OR of the association between CD133 expression and histological type (ADC vs. SCC) in NSCLC patients was dramatically changed after removed one study (Alamgeer.M 2013) (OR = 1.13, 95% CI: 0.93--1.38, *p* = 0.3; I^2^ = 0%, *p* = 0.522) (Figure [5C](#F5){ref-type="fig"}). Thus, it could not come to a conclusion that there was significant difference of CD133 expression level between ADC and SCC in NSCLC patients, which was different from Wang. W et al. \[[@R25]\].

Sensitive analysis and publication bias {#s2_6}
---------------------------------------

Sensitive analysis showed that regardless of which one study removed, pooled HRs of left studies on OS and DFS were remain robust and stable (see [Supplementary Figure S13](#SD1){ref-type="supplementary-material"} in Supplementary Material). Begg\'s funnel plot and Egger\'s publication bias plot were used to evaluate to the publication bias on OS (Figure [6A](#F6){ref-type="fig"}) and DFS (Figure [6B](#F6){ref-type="fig"}), respectively. No publication bias evidence was found in OS (Begg\'s test: *p* = 0.621; Egger\'s test: *p* = 0.318) or DFS (Begg\'s test: *p* = 0.858; Egger\'s test: *p* = 0.926). Same as in clinicopathological features (see [Supplementary Table S2](#SD1){ref-type="supplementary-material"} in Supplementary Material).

![Begg\'s funnel plot and Egger\'s test to evaluate the publication bias for (A) OS and (B) DFS](oncotarget-07-56526-g006){#F6}

DISSCUSION {#s3}
==========

Mainly benefit from tobacco control and improvements in early detection and treatment, mortality rates decreased for lung cancer by 45% and 8% since from 1990 to 2015 in men and women, respectively \[[@R57]\]. However, only a small proportion of lung cancers are currently detected early \[[@R57]\], and more effective methods are needed to reduce the morbidity and mortality of lung cancer.

The CSCs hypothesis elucidates that a small proportion of tumor cells drive the cancer growth, progression and recurrence \[[@R58]\], which is different from the classical stochastic hypothesis \[[@R59]\]. In a landmark experiment, Singh SK and his colleagues showed that injection of as few as 100 CD133^+^ tumor cells were tumorigenic but injection of 10^5^ CD133^−^ tumor cells were not, giving stable foundation for CSCs hypothesis in many solid tumors \[[@R60]\]. Recent studies showed that CD133 was a biomarker of putative CSCs in many solid tumors from brain \[[@R60]\] \[[@R61]\], lung \[[@R62], [@R63]\], liver \[[@R64]\], pancreas \[[@R65]\] \[[@R66]\] and colon \[[@R67]--[@R70]\]. However, controversies remain exist when referring to the prognostic value of CD133 in solid tumors \[[@R9], [@R20]--[@R48], [@R54], [@R55], [@R71]\].

In this meta-analysis, we tried to elucidate the potential prognostic and clinical value of CD133 by systematically reviewing and analyzing 32 eligible literature. Interestingly and notably particularly, we found that NSCLC patients with higher CD133 expression have shorter overall survival time only in Asian patients but not in Caucasian patients. It remains unknown why racial difference causes this significant difference. Recent studies showed that EGFR and EGFRvIII signaling are concerned with maintaining a CSCs phenotype \[[@R72]\]. The EGFR positive CSCs represented enhanced tumorigenic potential and highly invasive behavior whereas EGFR negative CSCs reduced their tumorigenic ability \[[@R73]\]. Furthermore, Mitsudomi et al. reported that the EGFR mutation rate was 32% in patients of East Asian compared with 7% in patients of non-Asian \[[@R74]\]. Probably as a consequence, we speculated that difference of mEGFR of CD133^+^ CSCs in different racial NSCLC patients might be the potential mechanism causing the significant difference on OS. Here to yonder, we speculated that only the intrinsic EGFR gene status of CSCs could predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients, which are effective target drugs for NSCLC patients with EGFR mutations. But so far, general method for detecting EGFR mutations in lung cancer is direct sequencing with a low sensitivity, which could not uncover the EGFR gene status of tumor factually \[[@R75]\]. Therefore, detecting EGFR gene status after identification and isolation of CSCs using CD133 in NSCLC patients might be preferable strategy for choosing EGFR-TKIs.

Certain limitations in our study might influence the results. Firstly, these eligible studies were incorporated with varying TNM stage. Secondly, detection methods and threshold value of CD133 expression level were not consistent. Thirdly, though we performed subgroup analysis to explore the significant heterogeneity and further stabilized and consolidated our results that NSCLC patients with higher CD133 expression had poor overall survival time only in Asian patients but not in Caucasian patients, we could not explain fully the potential heterogeneity on differentiated degree and lymph node metastasis. Fourthly, relevant data in several eligible studies were too limited to pool all studies for evaluating the association between CD133 expression level and these parameters, which might overrate the clinical value of CD133.

Therefore, added large-scale sample, high-quality, and interethnic studies will be required to confirm the prognostic and clinical value of CD133. Far more than, the association between CD133^+^ CSCs and EGFR mutation in NSCLC patients is further deserving of attention and exploration, which may provide a new therapeutic perspective on the treatment of NSCLC patients according to the expression of CD133 and the intrinsic EGFR gene status of CD133^+^ CSCs.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched PubMed, Embase, and Web of science to confirm relevant studies on CD133 expression level in NSCLC patients from each database since its inception up to May 4, 2016 without language restriction by using the keywords of CD133 and lung cancer (detail search strategy see Supplementary Material).

Inclusion and exclusion criteria {#s4_2}
--------------------------------

A study was selected when met the following criteria: (1) the study population were mainly NSCLC patients; (2) it investigated the prognostic role of CD133 with the survival outcomes and/or clinicopathological characteristics in NSCLC patients. The exclusion criteria: (1) meeting report, review, comment, or letter; (2) it was a reduplicative study whose data had been published in another study, and then left the complete one in this meta-analysis. Independently evaluations were performed by two authors (Engeng Chen and Zhiru Zeng) according to the inclusion and exclusion criteria.

Data extraction {#s4_3}
---------------

A double abstraction process was performed for data extraction (Engeng Chen and Zhiru Zeng). Disagreements were resolved by consulting the third author (Bingjun Bai). The following data were collected from eligible studies: the first author, publication year, race, number of NSCLC patients with CD133 measured, gender distribution, age, TNM stage, CD133 positive threshold, CD133 positive ratio, experimental method, primary outcomes (reported HR with its 95% CI on OS and DFS), and essential clinicopathological characteristics (T stage, N stage, M stage, TNM stage, smoking history, differentiation grade, and histological type).

Quality assessment of eligible studies {#s4_4}
--------------------------------------

The Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@R56]\] was used to evaluate the quality of each eligible study by two authors (Engeng Chen and Zhiru Zeng) independently. This scale ranges from 0 to 9 score, and we consider the study as a high quality study if the score is not less than 6.

Statistical analysis {#s4_5}
--------------------

The main purpose of this meta-analysis was to estimate the pooled HRs of OS and DFS, then to validate the hypotheses: that NSCLC patients with higher CD133 expression would have a shorter OS and DFS time. The secondary purpose was to estimate the pooled ORs to analyze the correlation between CD133 expression level and clinicopathological features, with the doubts: that is there any cause-and-effect relationship between CD133 and these features.

We analyzed each eligible study to obtain HR and DFS with corresponding 95% CI from the results of multivariate Cox\'s proportional hazards regression model reported in the study. Also we reconstructed and calculated the data from Kaplan-Meier survival curve using Engauge-Digitizer version 7.2 if there was no direct data in the study \[[@R76]\]. The ORs with corresponding 95% CIs were calculated according to the relevant parameters using chi-square test by SPSS version 21 (SPSS Inc. Chicago, USA) in eligible studies.

The following analyses were performed using Stata version 12 software (Stata Corporation, College Station, Texas, USA). Pooled HRs of OS and DFS and pooled ORs for the relationship between CD133 and clinicopathological features were calculated by using fixed-effects model if I-square \< 50%. Additionally, we used the Cochran\'s *Q*-test and I-square statistics to test for between-study heterogeneity \[[@R77]--[@R78]\]. Instead of fixed-effects, random-effects model was used if I-square \> 50% or corresponding *p* value \< 0.05. Furthermore, subgroup analysis and sensitive analysis were applied to assess the source of heterogeneity. The potential publication bias was tested by using Begg\'s test and Egger\'s test \[[@R79]--[@R80]\]. All statistics *p*-value \< 0.05 at two-tailed was considered statistically significant.

CONCLUSIONS {#s5}
===========

In summary, this meta-analysis showed that high expression level of CSCs marker CD133 was strongly in correlation with poor OS but not DFS in NSCLC patients. Subgroup analysis by race showed that NSCLC patients with higher CD133 expression had shorter overall survival time only in Asian patients but not in Caucasian patients, suggesting that differential prognostic value of CD133 expression in distinct ethnic group. Additionally, higher expression of CD133 was associated with poor differentiation and lymph node metastasis but there was no significant difference of CD133 expression between ADC and SCC in NSCLC patients. Therefore, added large-scale, prospective and clinical studies are required to further validate the prognostic and clinical value of CSCs marker CD133.
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